About
Inicure develops novel small molecule agonists targeting formyl peptide receptor-1 (FPR1) to treat infectious diseases such as UTIs and MRSA, aiming to address antibiotic-resistant bacterial infections.
Explore Inicure's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.